Skip to main content
SpringerLink
Log in

Epidermolysis bullosa

Aktuelle Entwicklungen in der Therapie der blasenbildenden Genodermatose

  • Fortbildung
  • Published:
hautnah dermatologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Kern JS et al. Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale. Trials 2019;20:350

  2. Panna Martinez DFM et al. BG01: Safety and efficacy of oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results of a 12-month interim analysis of the open-label phase from the EASE study. Br J Dermatol 2022;187:89

  3. Has C et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020;183:614-27

  4. Keith AR et al. Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa. Expert Opin Biol Ther 2020;20:911-23

  5. Petrof G et al. The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database. Br J Dermatol 2022;186:843-8

  6. McGrath JA et al. Epidermolysis bullosa. Br J Hosp Med (Lond) 2006;67:188-91

  7. Varki R et al. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. J Med Genet 2007;44:181-92

  8. Metelmann HR et al. Accelerated reepithelialization by triterpenes: proof of concept in the healing of surgical skin lesions. Skin Pharmacol Physiol 2015;28:1-11

  9. Lipovy B et al. Oleogel-S10 to Accelerate Healing of Donor Sites: Monocentric Results of Phase III Clinical Trial. Acta Chir Plast 2018;59:129-34

  10. Frew Q et al. Betulin wound gel accelerated healing of superficial partial thickness burns: Results of a randomized, intra-individually controlled, phase III trial with 12-months follow-up. Burns 2019;45:876-90

  11. Barret JP et al. Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program. Burns 2017;43:1284-94

  12. Pflugfelder A et al. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. Br J Dermatol 2015;172:926-

  13. Caroppo F et al. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab. J Eur Acad Dermatol Venereol 2022;36:e365-e7

  14. Clawson RC et al. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep 2021;16:69-71

  15. Shehadeh W et al. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol 2020;182:1495-7

  16. Wang Y et al. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report. Dermatol Ther 2021;34:e15130

  17. Zhou AG et al. Epidermolysis bullosa pruriginosa treated with dupilumab. Pediatr Dermatol 2021;38:526-7

  18. McGrath JA et al. Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features. Br J Dermatol 1994;130:617-25

  19. Cha CC et al. [Underrecognition of epidermolysis bullosa pruriginosa]. J Dtsch Dermatol Ges 2015;13:1035-8

  20. Kumar P et al. Epidermolysis bullosa pruriginosa affecting 3 successive generations. Skinmed 2013;11:308-9

  21. Ranugha PS et al. Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide - a report of two cases. Dermatol Ther 2014;27:60-3

  22. Pai VV et al. Epidermolysis bullosa pruriginosa: A report of two cases. Indian Dermatol Online J 2014;5:44-7

  23. Das JK et al. Epidermolysis bullosa pruriginosa - report of three cases. Indian J Dermatol Venereol Leprol 2005;71:109-11

  24. Senner S et al. Dupilumab for the treatment of adolescents with atopic dermatitis. Expert Rev Clin Immunol 2020;16:641-50

  25. Danial C et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol 2015;32:53-9

  26. Snauwaert JJ et al. Burden of itch in epidermolysis bullosa. Br J Dermatol 2014;171:73-8

  27. Papanikolaou M et al. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol 2021;184:816-25

  28. Jiang X et al. Epidermolysis Bullosa Pruriginosa Treated With Baricitinib. JAMA Dermatol 2021;157:1243-4

  29. Lauffer F et al. [Janus kinase inhibitors for the treatment of atopic dermatitis - evaluation of current data and practical experience]. Dermatologie (Heidelb) 2022;73:520-8

  30. Simpson EL et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020;183:242-55

Download references

Author information

Authors and Affiliations

  1. - Universitätsmedizin Göttingen -, Klinik f. Dermatologie/Venerologie/Allergologie, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland

    Jorge Frank

Authors
  1. Jorge Frank
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge Frank.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frank, J. Epidermolysis bullosa. hautnah dermatologie 39 (Suppl 1), 38–43 (2023). https://doi.org/10.1007/s15012-023-7668-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-023-7668-x

Search

Navigation